Management of chemotherapy in hemodialysis patients;Gestion des chimiothérapies chez les patients hé modialysés

Bulletin du Cancer

Volumn 99, Issue 3, 2012, Pages 371-380

  Janus, Nicolas ^a   Launay Vacher, Vincent ^a   Deray, Gilbert ^a   Thyss, Antoine ^b   Thariat, Juliette ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cytotoxic drugs; Dosing recommendations; Hemodialysis; Pharmacokinetics; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; PHARMACIST; PRESCRIPTION; REVIEW; SYSTEMATIC REVIEW;

EID: 84858650021     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1483     Document Type: Article

References (63)

1. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110 : 1376-84. (Pubitemid 47435612)
2. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30 : 548-56.
3. Sutherland GA, Glass J, Gabriel R. Increased incidence of malignancy in chronic renal failure. Nephron 1977; 18 : 182-4. (Pubitemid 8085140)
4. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002; 33 : 121-6.
5. Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS. Increased incidence of malignancy during chronic renal failure. Lancet 1975; 1 : 883-6.
6. Launay-Vacher V, Storme T, Izzedine H, Deray G. Pharmacokinetic changes in renal failure. Presse Med 2001; 30 : 597-604.
7. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009; 65 : 757-73.
8. Launay-Vacher V, Izzedine H, Baumelou A, Deray G. FHD: an index to evaluate drug elimination by hemodialysis. Am J Nephrol 2005; 25 : 342-51. (Pubitemid 41160993)
9. Akiba T, Okeda R, Tajima T. Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid directly injure myelinated fibers in tissue culture. Acta Neuropathol 1996; 92 : 8-13. (Pubitemid 26192076)
10. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47 : 2203-6. (Pubitemid 17074634)
11. Rengelshausen J, Hull WE, Schwenger V, Göggelmann C, Walter-Sack I, Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 2002; 39 : E10.
12. Gusella M, Rebeschini M, Cartei G, Ferrazzi E, Ferrari M, Padrini R. Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure. Ther Drug Monit 2005; 27 : 816-8. (Pubitemid 44391741)
13. Arai Y, Oyama T, Hotta K, Tomori A, Miyata Y. Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60 Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis. Nippon Shokakibyo Gakkai Zasshi 2008; 105 : 1482-8.
14. Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. Jpn J Clin Oncol 2010; 40 : 360-4.
15. Saito Y, Shimada K, Ohno Y, et al. 5-FU/l-LV therapy is useful for hemodialysis patients with advanced gastric cancer. Gan To Kagaku Ryoho 2011; 38 : 449-51.
16. Arellano M, Malet-Martino M, Martino R, Gires P. The anticancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 1998; 77 : 79-86. (Pubitemid 28029776)
17. eed. France : Méditions International, 2008.
18. SiteGPR. Available at: http://www.sitegpr.com/ (consulté 28 avril 2011).
19. Chung YL, Troy H, Judson IR, et al. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. Clin. Cancer Res 2004; 10 : 3863-70. (Pubitemid 38697622)
20. Dhillon S, Scott LJ. Capecitabine: in advanced gastric or oesophagogastric cancer. Drugs 2007; 67 : 601-10. (Pubitemid 46440317)
21. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49 : 225-34. (Pubitemid 34185596)
22. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 : 1748-56. (Pubitemid 19272848)
23. Li YF, Fu S, Hu W, et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007; 17 : 739-63. (Pubitemid 47063315)
24. Chatelut E, Rostaing L, Gualano V, et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron 1994; 66 : 157-61. (Pubitemid 24028054)
25. Prestayko AW, D'Aoust JC, Issell BF, Crooke ST. Cisplatin (cisdiamminedichloroplatinum II). Cancer Treat Rev 1979; 6 : 17-39.
26. Tanabe N, Goto M, Morita H, et al. Pharmacokinetics of cisdiammine-dichlor-platin in a hemodialysis patient. Cancer Invest 1991; 9 : 629-35.
27. Gorodetsky R, Vexler A, Bar-Khaim Y, Biran H. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995; 17 : 203-6.
28. Kurisu A, Hata T, Owada A. Full-dose chemotherapy for esophageal cancer patient under hemodialysis. Nephron 2002; 92 : 960. (Pubitemid 36151392)
29. de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005; 44 : 1135-64. (Pubitemid 41483700)
30. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61 : 1495-501. (Pubitemid 34304511)
31. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981; 19 : 443-51. (Pubitemid 11067793)
32. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993; 53 : 1037-42. (Pubitemid 23087904)
33. Mencoboni M, Olivieri R, Vannozzi MO, Schettini G, Viazzi F, Ghio R. Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient. Chemotherapy 2006; 52 : 147-50. (Pubitemid 43760312)
34. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54 : 987-92. (Pubitemid 24085451)
35. Yoshida H, Goto M, Honda A, et al. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Cancer Chemother Pharmacol 1994; 33 : 450-4. (Pubitemid 24082336)
36. Weenen H, Lankelma J, Penders PG, et al. Pharmacokinetics of 4′-epi-doxorubicin in man. Invest New Drugs 1983; 1 : 59-64.
37. Gori S, Rulli A, Mosconi AM, Sidoni A, Colozza M, Crinò L. Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. Tumori 2006; 92 : 364-5. (Pubitemid 44525319)
38. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984; 44 : 379-82. (Pubitemid 14177767)
39. Watanabe R, Takiguchi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003; 88 : 25-30. (Pubitemid 36241213)
40. Holthuis JJ, Van de Vyver FL, van Oort WJ, Verleun H, Bakaert AB, De Broe ME. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Cancer Treat Rep 1985; 69 : 1279-82. (Pubitemid 16217009)
41. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14 : 257-67. (Pubitemid 26020022)
42. Inoue A, Saijo Y, Kikuchi T, et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004; 15 : 51-4. (Pubitemid 38139603)
43. D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46 : 2566-71. (Pubitemid 16120732)
44. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9 : 491-8.
45. Masumori N, Kunishima Y, Hirobe M, et al. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Jpn J Clin Oncol 2008; 38 : 182-5. (Pubitemid 351419741)
46. Kiani A, Köhne C-H, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003; 51 : 266-70. (Pubitemid 36469958)
47. Gupta E, Vyas V, Ahmed F, Sinko P, Cook T, Rubin E. Pharmacokinetics of orally administered camptothecins. Ann N Y Acad Sci 2000; 922 : 195-204. (Pubitemid 32050254)
48. Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie 2002; 25 : 60-3. (Pubitemid 34224995)
49. Vénat-Bouvet L, Saint-Marcoux F, Lagarde C, Peyronnet P, Lebrun-Ly V, Tubiana-Mathieu N. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered. Anticancer Drugs 2007; 18 : 977-80. (Pubitemid 47220719)
50. Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010; 21 : 1395-403.
51. Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21 : 2664-72. (Pubitemid 46606309)
52. Matoba S, Sawada T, Toda S, et al. Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer. Gan To Kagaku Ryoho 2008; 35 : 673-5.
53. Ohnishi T, Kanoh T, Shiozaki K, et al. FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Gan To Kagaku Ryoho 2007; 34 : 1299-302.
54. Fujita M, Koide T, Katayama T, et al. The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy. Gan To Kagaku Ryoho 2009; 36 : 1379-82.
55. Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 2011; Available at: http://www.ncbi.nlm.nih. gov/pubmed/21499694 (consulté 14 juin 2011).
56. Shitara K, Munakata M, Muto O, et al. Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysis. Jpn J Clin Oncol 2007; 37 : 540-3. (Pubitemid 47335473)
57. Woo MH, Gregornik D, Shearer PD, Meyer WH, Relling MV. Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 1999; 43 : 92-6. (Pubitemid 29048354)
58. Yokoyama Y, Futagami M, Higuchi T, Mizunuma H. Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis - case report. Eur J Gynaecol Oncol 2006; 27 : 437-9. (Pubitemid 44407890)
59. Baur M, Fazeny-Doerner B, Olsen SJ, Dittrich C. High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature. Int J Gynecol Cancer 2008; 18 : 564-70. (Pubitemid 351668316)
60. Mori M, Takeda E, Sakai K, et al. A case of non-small cell lung carcinoma successfully treated with carboplatin and weekly paclitaxel under renal dysfunction. Gan To Kagaku Ryoho 2004; 31 : 2061-4.
61. Krikorian A, Rahmani R, Bromet M, Bore P, Cano JP. Pharmacokinetics and metabolism of navelbine. Semin Oncol 1989; 16 : 21-5.
62. Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 2009; 5 : 450-62.
63. Thyss A, Janus N, Launay-Vacher V, et al. Management of systemic anticancer treatment in patients (pts) under chronic dialysis: a raising concern and an emerging population - preliminary results of the French CANDY (CANcer and DialYsis) study. J Clin Oncol 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2011; 29(15 suppl (May 20 Supplement)) : e13562.